Manning Paul's most recent trade in Liquidia Corp was a trade of 254,038 Common Stock done at an average price of $28.7 . Disclosure was reported to the exchange on Aug. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 28.67 per share. | 28 Aug 2025 | 254,038 | 505,058 (1%) | 0% | 28.7 | 7,283,269 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 27.62 per share. | 28 Aug 2025 | 188,232 | 759,096 (2%) | 0% | 27.6 | 5,198,968 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 27.94 per share. | 28 Aug 2025 | 154,337 | 947,328 (3%) | 0% | 27.9 | 4,312,176 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Sale of securities on an exchange or to another person at price $ 29.14 per share. | 28 Aug 2025 | 74,230 | 430,828 (1%) | 0% | 29.1 | 2,163,062 | Common Stock |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Purchase of securities on an exchange or from another person at price $ 116.95 per share. | 11 Aug 2025 | 20 | 80 (0%) | 0% | 117.0 | 2,339 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 4.67 per share. | 25 Jun 2025 | 1,070,663 | 2,213,069 | - | 4.7 | 4,999,996 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 18,396 | 38,755 (0%) | 0% | 0 | Common Stock | |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Paul B. Manning | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.75 per share. | 30 May 2025 | 750,000 | 2,841,704 | - | 2.8 | 2,062,500 | Common Stock |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 26,658 | 266,312 (0%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 26,658 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.00 per share. | 13 Feb 2025 | 13,329 | 252,983 (0%) | 0% | 77 | 1,026,333 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 6.00 per share. | 16 Dec 2024 | 750,000 | 1,303,752 | - | 6 | 4,500,000 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 6.00 per share. | 16 Dec 2024 | 500,000 | 1,142,406 | - | 6 | 3,000,000 | Common Stock |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.00 per share. | 09 Dec 2024 | 8,695 | 239,654 (0%) | 0% | 78 | 678,210 | Common Stock |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2024 | 34,492 | 34,492 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Dec 2024 | 22,994 | 248,349 (0%) | 0% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 18,426,966 | 26,278,094 (101%) | 71% | - | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 9,213,483 | 9,213,483 | - | - | Series A Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 9,213,483 | 9,213,483 | - | - | Series B Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 4,494,382 | 5,976,101 (23%) | 17% | - | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 2,247,191 | 2,247,191 | - | - | Series B Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 22 Nov 2024 | 2,247,191 | 2,247,191 | - | - | Series A Warrants (right to buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Nov 2024 | 450,000 | 25,828,094 (100%) | 1% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2024 | 2,675,611 | 0 (0%) | 10% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2024 | 891,870 | 891,870 (3%) | 3% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2024 | 891,870 | 891,870 (3%) | 3% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Sep 2024 | 891,870 | 891,870 (3%) | 3% | 0 | Common Stock | |
| Liquidia Corp | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 8.90 per share. | 12 Sep 2024 | 337,078 | 816,311 (2%) | 1% | 8.9 | 2,999,994 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 27 Jun 2024 | 1,333,333 | 1,333,333 | - | 2.2 | 2,999,999 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2024 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,359 | 299,689 (1%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp | Manning Paul | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 36,005 | 243,357 (0%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp | Manning Paul | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 36,005 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.74 per share. | 08 Feb 2024 | 18,002 | 225,355 (0%) | 0% | 62.7 | 1,129,445 | Common Stock |
| Liquidia Corp | Manning Paul B. | Director | Purchase of securities on an exchange or from another person at price $ 7.16 per share. | 14 Dec 2023 | 279,330 | 279,330 (0%) | 0% | 7.2 | 2,000,003 | Common Stock |
| Sensient Technologies Corp | Manning Paul | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.33 per share. | 11 Dec 2023 | 9,686 | 207,352 (0%) | 0% | 61.3 | 594,042 | Common Stock |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 42,442 | 42,442 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Manning Paul | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2023 | 28,294 | 217,038 (0%) | 0% | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Paul B. Manning | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.63 per share. | 17 Nov 2023 | 100,000 | 16,566,667 | - | 1.6 | 163,000 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.90 per share. | 16 Aug 2023 | 16,466,667 | 16,466,667 | - | 0.9 | 14,820,000 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 5.02 per share. | 24 Jul 2023 | 200,000 | 7,851,128 (30%) | 0% | 5.0 | 1,004,000 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2023 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2023 | 20,000 | 20,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 100,756 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 100,756 | 239,122 (0%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.49 per share. | 09 Feb 2023 | 50,378 | 188,744 (0%) | 0% | 72.5 | 3,651,901 | Common Stock |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2022 | 35,160 | 35,160 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2022 | 23,440 | 138,366 (0%) | 0% | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.00 per share. | 31 Oct 2022 | 1,500,000 | 1,642,202 | - | 2 | 3,000,000 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2022 | 14,240 | 14,240 | - | - | Stock Option (Right to Buy) | |
| Verrica Pharmaceuticals Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.10 per share. | 05 Jul 2022 | 4,761,904 | 13,651,128 (52%) | 18% | 2.1 | 9,999,998 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 20,000 | 20,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Liquidia Corp | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 5.10 per share. | 18 Apr 2022 | 392,156 | 392,156 (1%) | 1% | 5.1 | 1,999,996 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 435,674 | 435,674 (1%) | 1% | 0 | Common Stock | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 17,800 | 123,826 (0%) | 0% | 0 | Common Stock | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2022 | 17,800 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.43 per share. | 10 Feb 2022 | 8,900 | 114,926 (0%) | 0% | 83.4 | 742,527 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.77 per share. | 02 Feb 2022 | 58,000 | 92,202 | - | 7.8 | 450,660 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.84 per share. | 02 Feb 2022 | 50,000 | 142,202 | - | 7.8 | 392,000 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.77 per share. | 02 Feb 2022 | 45,000 | 2,065,102 | - | 7.8 | 349,650 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.84 per share. | 02 Feb 2022 | 26,602 | 2,091,704 | - | 7.8 | 208,560 | Common Stock |
| Taysha Gene Therapies Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.77 per share. | 02 Feb 2022 | 22,000 | 22,000 | - | 7.8 | 170,940 | Common Stock |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2021 | 26,084 | 26,084 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Dec 2021 | 17,390 | 106,026 (0%) | 0% | 0 | Common Stock | |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.45 per share. | 02 Dec 2021 | 30,023 | 8,129,417 (31%) | 0% | 9.4 | 283,717 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 9.22 per share. | 02 Dec 2021 | 19,977 | 8,149,394 (31%) | 0% | 9.2 | 184,188 | Common Stock |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 13.19 per share. | 24 Nov 2021 | 2,202 | 34,202 | - | 13.2 | 29,044 | Common Stock |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 12.54 per share. | 23 Nov 2021 | 20,000 | 32,000 | - | 12.5 | 250,800 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 20,000 | 20,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | 29 Jul 2021 | 1,669,303 | 0 | - | - | Series B Preferred Stock | ||
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 8.00 per share. | 29 Jul 2021 | 1,625,000 | 1,681,000 | - | 8 | 13,000,000 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | 29 Jul 2021 | 1,361,069 | 0 | - | - | Series B Preferred Stock | ||
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | 29 Jul 2021 | 679,158 | 679,158 | - | - | Common Stock | ||
| Candel Therapeutics Inc | Paul B. Manning | Director, Ten Percent Owner | 29 Jul 2021 | 553,752 | 553,752 | - | - | Common Stock | ||
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 7.36 per share. | 27 Jul 2021 | 36,000 | 36,000 | - | 7.4 | 264,834 | Common Stock |
| Candel Therapeutics Inc | Paul B. Manning | Director | Purchase of securities on an exchange or from another person at price $ 7.30 per share. | 27 Jul 2021 | 20,000 | 56,000 | - | 7.3 | 145,944 | Common Stock |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 20.98 per share. | 14 May 2021 | 12,000 | 12,000 | - | 21.0 | 251,760 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.52 per share. | 13 Apr 2021 | 198,413 | 737,646 (2%) | 0% | 2.5 | 500,001 | Common Stock |
| Verrica Pharmaceuticals Inc | Paul Manning | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 14.75 per share. | 25 Mar 2021 | 739,830 | 739,830 (2%) | 2% | 14.8 | 10,912,493 | Common Stock |
| Liquidia Corp | Paul B. Manning | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 21,385 | 21,385 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2021 | 39,100 | 0 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 29,059 | 29,059 | - | - | Performance Stock Unit | |
| Sensient Technologies Corp | Paul Manning | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2020 | 19,373 | 88,636 (0%) | 0% | 0 | Common Stock |